Compare AbbVie Inc (ABBV) vs iShares MSCI Taiwan ETF (EWT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI Taiwan ETF — how do they compare? AbbVie Inc trades at $253.58 (market cap $449.91B), while iShares MSCI Taiwan ETF trades at $103.45. The key difference: AbbVie Inc pays a 2.72% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals.
| ABBV | EWT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $111.53 |
52-Week Low | $184.85 | $57.66 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
EWT trades at $107.27, up 2.3% with strong bullish momentum from moving averages. The ETF has more than doubled in the past year, driven by Taiwan's semiconductor sector dominance and AI infrastructure demand. Technical indicators show neutral oscillators but overall buy signals dominate. Recent news highlights geopolitical tensions and semiconductor supply chain importance as key drivers.
Outlook remains positive given Taiwan's critical role in global tech supply chains, though stretched valuations and China-Taiwan geopolitical risks pose significant headwinds. The concentration in tech stocks like TSMC offers growth exposure but increases vulnerability to sector-specific downturns and trade disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →
